In the rapidly evolving landscape of drug discovery, the ability to integrate high-quality research findings into knowledge graphs is paramount. For over twenty years, our scientists have curated the relationships between genes, drugs, diseases, and pathways to power Ingenuity Pathway Analysis. Now, these data are available via our QIAGEN Biomedical KB-HD, which provides direct access […]
Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases Clinical exome testing is revolutionizing the diagnosis […]
Watch NowIn this training, you will learn how to analyze viral samples using QIAGEN CLC Genomics Workbench. This webinar will focus on bioinformatics workflows and data interpretation using H5N1 as an […]
Watch NowMore and more biopharma and academic groups are looking to process a large number of samples simultaneously or for a quicker turnaround time. This webinar will introduce a flexible and […]
Watch NowThere is a strong interest in the scientific community to use public (GEO, SRA, TCGA, LINCS, etc.) omics (RNA-seq, scRNA-seq, microarray, proteomics, etc.) data for a variety of discoveries. This […]
Watch NowYou’re invited to attend the 2024 Clinician’s Roundtable, a virtual event where medical directors and oncologists will discuss how to better interpret genomic test results to tailor treatment strategies for […]
Watch NowIngenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships […]
Watch Now
